• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate

Video

Until more data is available, it’s difficult for a practice or physician group to make an accurate assessment of whether or not 2-sided risk is appropriate, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists. Physicians would need to see clear metrics in order to know if they will be achievable.

Until more data is available, it’s difficult for a practice or physician group to make an accurate assessment of whether or not 2-sided risk is appropriate, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists. Physicians would need to see clear metrics in order to know if they will be achievable.

Transcript (slightly modified)

What are your thoughts on physicians taking on 2-sided risk?

I think it’s a really complex question, and something that we have to think thoroughly through. I think a lot of the panelists and the audience as well made a very valid point that until a lot of the data is available it’s very difficult to make an accurate assessment of whether or not 2-sided risk is appropriate for a practice and a physician group to know whether or not they’ll be able to be successful and meet those metrics.

What incentives do you think might be necessary for physicians to want to take on 2-sided risk?

There would really have to be some pretty detailed, not as much guarantees but some really clear metrics so they know if they’re going to be achievable in order for the physicians to take 2-sided risk. I think a lot of those are surrounding making sure we’re all on the same page with accurately measuring quality and what that means to a patient. So some of those could be whether it’s financial incentives, whether it’s ensuring that we’re in compliance with certain measures that the physicians feels is really going to drive quality for the oncology patient, making sure that the totality of the patient is really looked upon versus just what’s happening in the clinic or the oncology office.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.